SEARCH

SEARCH BY CITATION

References

  • AHN, K., SISNEROS, A.M., HERMAN, S.B., PAN, S.M., HUPE, D., LEE, C., NIKAM, S., CHENG, X.-M., DOHERTY, A.M., SCHROEDER, R.L., HALEEN, S.J., KAW, S., EMOTO, N. & YANAGISAWA, M. (1998). Novel selective quinazoline inhibitors of endothelin-converting enzyme-1. Biochem. Biophys. Res. Commun., 243, 184190.
  • BACON, C.R., CARY, N.R.B. & DAVENPORT, A.P. (1996). Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ. Res., 79, 794801.
  • BARKER, S., KHAN, N.Q., WOOD, E.G. & CORDER, R. (2001). Effect of an antisense oligodeoxynucleotide to endothelin-converting enzyme-1c (ECE-1c) on ECE-1c mRNA, ECE-1 protein and endothelin-1 synthesis in bovine pulmonary artery smooth muscle. Mol. Pharmacol., 59, 163169.
  • BAX, W.A., AGHAI, Z., VAN TRICHT, C.L.J., WASSENAAR, C. & SAXENA, P.R. (1994). Different endothelin receptors involved in endothelin-1 and sarafotoxin S6B-induced contractions of the human isolated coronary artery. Br. J. Pharmacol., 113, 14711479.
  • DASHWOOD, M.R., ALLEN, S.P., LUU, T.N. & MUDDLE, J.R. (1994). The effect of the ETA receptor antagonist, FR139317, on [125I]-ET-1 binding to the atherosclerotic human coronary artery. Br. J. Pharmacol., 112, 386389.
  • DAVENPORT, A.P., O'REILLY, G. & KUC, R.E. (1995). Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br. J. Pharmacol., 114, 110116.
  • DEC, G.W. & FUSTER, V. (1994). Idiopathic dilated cardiomyopathy. New. Engl. J. Med., 331, 15641575.
  • DOHERTY, A.M., PATT, W.C., EDMUNDS, J.J., BERRYMAN, K.A., REISDORPH, B.R., PLUMMER, M.S., SHAHRIPOUR, A., LEE, C., CHENG, X-M., WALKER, D.M., HALEEN, S.J., KEISER, J.A., FLYNN, M.A., WELCH, K.M., HALLAK, H., TAYLOR, D.G. & REYNOLDS, E.E. (1995). Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J. Med. Chem., 38, 12591263.
  • GOLDIE, R.G., D'APRILE, A.C., SELF, G.J., RIGBY, P.J. & HENRY, P.J. (2000). Influence of endothelin-1(1–31) on smooth muscle tone and cholinergic nerve-mediated contraction in rat isolated trachea. J. Cardiovasc. Pharmacol., 36, (Suppl. 1) S228S231.
  • HANSON, G.C., ANDERSSON, K.E., GYLLSTEDT, E., HOGESTATT, E.D. & LINDBERG, B.F. (1997). Hydrolysis of big endothelin-1 by a serine protease in the membrane fraction of human lung. Regulatory Peptides, 68, 6369.
  • HAYASAKI-KAJIWARA, Y., NAYA, N., AHIMAMURA, T., IWASAKI, T. & NAKAJIMA, M. (1999). Endothelin generating pathway through endothelin1–31 in human cultured bronchial smooth muscle cells. Br. J. Pharmacol., 127, 14151421.
  • HAYNES, W.G. & WEBB, D.J. (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, 344, 852854.
  • HOLM, P. & FRANCO-CERECEDA, A. (1996). Tissue concentrations of endothelins and functional effects of endothelin receptor activation in human arteries and veins. J. Thorac. Cardiovasc. Surgery, 112, 264272.
  • INUI, D., YOSHIZUMI, M., OKISHIMA, N., HOUCHI, H., TSUCHIYA, K., KIDO, H. & TAMAKI, T. (1999). Mechanism of endothelin-1-(1-31)-induced calcium signalling in human coronary artery smooth muscle cells. Am. J. Physiol., 276, E1067E1072.
  • KAARTINEN, M., PENTTILA, A. & KOVANEN, P.T. (1994). Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation, 90, 16691678.
  • KAW, S., HECKER, M., SOUTHAN, G.J., WARNER, T.D. & VANE, J.R. (1992). Characterization of serine protease-derived metabolites of big endothelin in the cytosolic fraction from human polymorphonuclear leukocytes. J. Cardiovasc. Pharmacol., 20, (Suppl. 12) S22S24.
  • KIDO, H., NAKANO, A., OKISHIMA, N., WAKABAYASHI, H., KISHI, F., NAKAYA, Y., YOSHIZUMI, M. & TAMAKI, T. (1998). Human chymase, an enzyme forming novel bioactive 31-amino acid length endothelins. Biol. Chem., 379, 885891.
  • KISHI, F., MINAMI, K., OKISHIMA, N., MURAKAMI, M., MORI, S., YANO, M., NIWA, Y. & KIDO, H. (1998). Novel 31 amino-acid-length endothelins cause constriction of vascular smooth muscle. Biochem. Biophys. Res. Commun., 248, 387390.
  • KYRIAKIDES, Z.S., KREMASTINOS, D.T., BOFILIS, E., TOUSOULIS, D., ANTONIADIS, A. & WEBB, D.J. (2000). Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart, 84, 176182.
  • LOVE, M.P., FERRO, C.J., HAYNES, W.G., PLUMPTON, C., DAVENPORT, A.P., WEBB, D.J. & MCMURRAY, J.J.V. (2000). Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc. Res., 47, 166172.
  • MAGUIRE, J.J., AHN, K. & DAVENPORT, A.P. (1999). Inhibition of big endothelin-1 (big ET-1) responses in endothelium-denuded human coronary artery by the selective endothelin converting enzyme-1 (ECE-1) inhibitor PD159790. Br. J. Pharmacol., 126, U102.
  • MAGUIRE, J.J. & DAVENPORT, A.P. (1995). ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br. J. Pharmacol., 115, 191197.
  • MAGUIRE, J.J. & DAVENPORT, A.P. (1998). Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br. J. Pharmacol., 125, 238240.
  • MAGUIRE, J.J. & DAVENPORT, A.P. (1999). In vitro vasoconstrictor activity of novel peptide endothelin-1(1-31) is due to conversion to endothelin-1(1-21) in human internal mammary artery by an enzyme other than endothelin-converting enzyme. Br. J. Pharmacol., 128, U35.
  • MAGUIRE, J.J., JOHNSON, C.M., MOCKRIDGE, J.W. & DAVENPORT, A.P. (1997a). Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br. J. Pharmacol., 122, 16471654.
  • MAGUIRE, J.J., KUC, R.E. & DAVENPORT, A.P. (1997b). Affinity and selectivity of PD156707, a novel non-peptide endothelin antagonist, for human ETA and ETB receptors. J. Pharmacol. Exp. Therap., 280, 11021108.
  • NAGATA, N., NIWA, Y. & NAKAYA, Y. (2000). A novel 31-amino-acid-length endothelin, ET-1(1-31), can act as a biologically active peptide for vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 275, 595600.
  • NAKANO, A., KISHI, F., MINAMI, K., WAKABAYASHI, H., NAKAYA, Y. & KIDO, H. (1997). Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J. Immunol., 159, 19871992.
  • NIWA, Y., NAGATA, N., OKA, M., TOYOSHIMA, T., AKIYOSHI, H., WADA, T. & NAKAYA, Y. (2000). Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by chymase. Life Sci., 67, 11031109.
  • OHNAKA, K., TAKAYANAGI, R., NISHIKAWA, M., HAJI, M. & NAWATA, H. (1993). Purification and characterisation of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. J. Biol. Chem., 268, 2675926766.
  • OKISHIMA, N., HAGIWARA, Y., SEITO, T., YANO, M. & KIDO, H. (1999). Specific sandwich-type enzyme immunoassays for smooth muscle constricting novel 31-amino acid endothelins. Biochem. Biophys. Res. Commun., 256, 15.
  • OPGAARD, O.S., CANTERA, L., ADNER, M. & EDVINSSON, L. (1996). Endothelin-A and -B receptors in human coronary artery and veins. Regulatory Peptides, 63, 149156.
  • PATTERSON, K., MACNAUL, R., RUBANYI, G.M. & PARKER-BOTELLO, L.H. (1990). Separation and biological activity of the chymotrypsin and cathepsin G cleavage products of big endothelin(1-39) [Abstract]. FASEB J., 4, A909.
  • PLUMPTON, C., ASHBY, M.J., KUC, R.E., O'REILLY, G. & DAVENPORT, A.P. (1996). Expression of endothelin peptides and mRNA in the human heart. Clin. Sci., 90, 3746.
  • PLUMPTON, C., KALINKA, S., MARTIN, R.C., HORTON, J.K. & DAVENPORT, A.P. (1994). Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays. Clin. Sci., 87, 245251.
  • REYNOLDS, E.E., KEISER, J.A., HALEEN, S.J., WALKER, D.M., OLSZEWSKI, B., SHROEDER, R.L., TAYLOR, D.G., HWANG, O., WELCH, K.M., FLYNN, M.A., THOMPSON, D.M., EDMUNDS, J.J., BERRYMAN, K.A., PLUMMER, M., CHENG, X-M., PATT, W.C. & DOHERTY, A.M. (1995). Pharmacological characterization of PD156707, an orally active ETA receptor antagonist. J. Pharmacol. Exp. Therap., 273, 14101417.
  • RUSSELL, F.D. & DAVENPORT, A.P. (1999). Secretory pathways in endothelin synthesis. Br. J. Pharmacol., 126, 391398.
  • STRACHAN, F.E., SPRATT, J.C., WILKINSON, I.B., JOHNSTON, N.R., GRAY, G.A. & WEBB, D.J. (1999). Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension, 33, 581585.
  • TAKEJI, T., NAKAYA, Y., KAMADA, M., MAEDA, K., SAIJO, Y., MITANI, R., IRAHARA, M. & AONO, T. (2000). Effect of novel vasoconstrictor endothelin-1(1-31) on human umbilical artery. Biochem. Biophys. Res. Commun., 270, 622624.
  • VERHAAR, M.C., STRACHAN, F.E., NEWBY, D.E., CRUDEN, N.L., KOOMANS, H.A., RABELINK, T.J. & WEBB, D.J. (1998). Endothelin-A receptor antagonist mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation, 97, 752756.
  • WOODS, M., MITCHELL, J.A., WOOD, E.G., BARKER, S., WALCOT, N.R., REES, G.M. & WARNER, T.D. (1999). Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for an intracellular endothelin-converting enzyme. Mol. Pharmacol., 55, 902909.
  • YANAGISAWA, H., HAMMER, R.E., RICHARDSON, J.A., EMOTO, N., WILLIAMS, S.C., TAKEDA, S.-I., CLOUTHIER, D.E. & YANAGISAWA, M. (2000). Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine development. J. Clin. Invest., 105, 13731382.
  • YANAGISAWA, M., KURIHARA, H., KIMURA, S., TOMOBE, Y., KOBAYASHI, M., MITSUI, Y., YAZAKI, Y., GOTO, K. & MASAKI, T. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411415.
  • YANAGISAWA, H., YANAGISAWA, M., KAPUR, R.P., RICHARDSON, J.A., WILLIAMS, S.C., CLOUTHIER, D.E., DE WIT, D., EMOTO, N. & HAMMER, R.E. (1998). Dual genetic pathways of endothelin-mediated intercellular signalling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development, 125, 825836.
  • YOSHIZUMI, M., INUI, D., OKISHIMA, N., HOUCHI, H., TSUCHIYA, K., WAKABAYASHI, H., KIDO, H. & TAMAKI, T. (1998a). Endothelin-1-(1-31), a novel vasoactive peptide, increases [Ca2+]i in human coronary artery smooth muscle cells. Eur. J. Pharmacol., 348, 305309.
  • YOSHIZUMI, M., KIM, S., KAGAMI, S., HAMAGUCHI, A., TSUCHIYA, K., HOUCHI, H., IWAO, H., KIDO, H. & TAMAKI, T. (1998b). Effect of endothelin (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br. J. Pharmacol., 125, 10191027.